 |
 |
 |
 |
 |
1) Even though all samples are handled as if they are
infected, should samples known to be positive for either HIV
or hepatitis be sorted?
2) Should human derived cell lines be treated the same as
those coming from patients?
This cell line question seems to me to be particularly messy
because of the time and cost involved in testing and cleanup
if every LIVE human derived cell line is treated as if infected
when run on the cytometer.
3) Is there a governing body (ISAC?, etc.) that has written
guidelines specifically targeted at flow cytometry?
I realize some of this has been discussed before on the net
and that basically there was no consensus. As usual, these
questions are driven by investigators wanting to run
experiments for which there is no policy.
Justin Fishbaugh
University of Iowa
Flow Cytometry Facility
internet: justin-fishbaugh@uiowa.edu
|
|
|
|
|
|
CD-ROM Vol 3 was produced by Monica M. Shively and other staff at the
Purdue University Cytometry Laboratories and distributed free of charge
as an educational service to the cytometry community.
If you have any comments please direct them to
Dr. J. Paul Robinson, Professor & Director,
PUCL, Purdue University, West Lafayette, IN 47907.
Phone: (765)-494-0757;
FAX(765) 494-0517;
Web